We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Denosumab.
- Abstract
The article provides information the osteoporosis drug for postmenopausal women, the Denosumab, from Amgen Inc. Denosumab is claimed as a humanised monoclonal antibody that blocks the interaction with the receptor activator of nuclear factor-κβ ligand (RANKL) on the surface of osteoclasts. The drug is said having been approved based on a large phase III randomised trial of 7,868 aged 60-90 years, whose bone mineral density T score is less than -2.5.
- Subjects
OSTEOPOROSIS in women; AMGEN Inc.; MONOCLONAL antibody probes; LIGANDS (Biochemistry); BONE density; THERAPEUTICS
- Publication
Australian Prescriber, 2010, Vol 33, Issue 6, p194
- ISSN
0312-8008
- Publication type
Article